REMARKS

The Examiner states that restriction of the pending claims to one of the following twelve groups is required under 35 U.S.C. § 121:

I. Claims 1 and 3 drawn to methods of producing an immunoglobulin comprising administering an antigen to a nonhuman animal and recovering said immunoglobulin by isolating B cells, immortalizing the B cells, and recovering the immunoglobulin from the immortalized B cells.

II. Claims 1 and 3-4, drawn to methods of producing an immunoglobulin comprising administering an antigen to a nonhuman animal and recovering said immunoglobulin by isolating B cells, immortalizing the B cells, recovering genes encoding the variable region of the immunoglobulin from the immortalized cells, expressing the genes to produce immunoglobulin and recovering said immunoglobulin.

III. Claims 5, 9, 13, 21, 35-36 and 62, drawn to recombinant DNA molecules comprising a nucleotide sequence encoding an immunoglobulin and vectors comprising the recombinant DNA.

IV. Claims 7, 11, 15, 23, 37 and 61, drawn to a cell modified to contain a recombinant DNA molecule comprising a nucleotide sequence encoding an immunoglobulin.

V. Claims 8, 12, 16, 24 and 38, drawn to a method to produce an antibody comprising culturing a cell modified to contain a recombinant DNA molecule comprising a nucleotide sequence encoding an immunoglobulin.

VI. Claim 17, drawn to an immortalized B cell which secretes an immunoglobulin with a human variable region.

VII. Claim 18, drawn to methods of producing an immunoglobulin by culturing an immortalized B cell which secretes an immunoglobulin with a human variable region.

VIII. Claims 19-20, 26, 34, 46-60 and 72, drawn to an isolated human antibody or immunoglobulin with a human variable region specific for an antigen.

IX. Claim 39, drawn to the use of an antibody for treating an autoimmune disease.

X. Claims 64-71, drawn to methods of producing a human antibody that binds to and modulates the activity of a leukocyte marker comprising administering the marker to a mouse, screening a mouse for human antibody that binds to the marker, isolating antibody from a mouse that has the human antibody and determining whether the antibody modulates the activity of the leukocyte marker.

XI. Claims 73-84, drawn to methods of modulating the activity of a leukocyte marker comprising contacting a cell with an antibody that binds to and modulates the activity of the leukocyte marker.

XII. Claims 85-99, drawn to methods of detecting the presence of a leukocyte marker comprising contacting a sample or cell with an antibody.

Applicants elect Group VIII (claims 19-20, 26, 34, 46-60 and 72) drawn to an isolated human antibody or immunoglobulin with a human variable region specific for an antigen without traverse.

The Examiner states that applicants must also elect a single disclosed species (*e.g.*, a single antigen from the list recited in claims 20, 24, 26, 38, 46, 64-65, 73, 83-85 and 93). Applicants elect IL-6 as the species for initial examination. Applicants make this election without waiver of their right to request rejoinder of withdrawn claims should a generic claim be finally held allowable.

Applicants make this election expressly without waiver of their right to continue to prosecute and to obtain claims to the non-elected subject matter either in this application or by filing divisional or continuing applications claiming priority and benefit from this application.

The Examiner is invited to telephone the undersigned to discuss any issue pertaining to this response. Applicants request favorable consideration of the application and early allowance of the pending claims.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
R. Minako Pazdera (Reg. No. 46,984)
Anupama R. Sawkar (Reg. No. 59,399)
Agents for Applicants

FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax: (212) 596-9090